Business Description
Aequus Pharmaceuticals Inc
NAICS : 325410
SIC : 3741
ISIN : CA0076361033
Total Employee Number:
14Description
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products namely Tacrolimus IR and Vistitan.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Equity-to-Asset | -35.17 | |||||
Debt-to-Equity | -0.88 | |||||
Debt-to-EBITDA | -27.41 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -296.11 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -42.5 | |||||
3-Year EBITDA Growth Rate | -11.9 | |||||
3-Year EPS without NRI Growth Rate | -26 | |||||
3-Year FCF Growth Rate | -10.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 80.78 | |||||
9-Day RSI | 68.81 | |||||
14-Day RSI | 62.29 | |||||
3-1 Month Momentum % | 420 | |||||
6-1 Month Momentum % | 4 | |||||
12-1 Month Momentum % | -48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.03 | |||||
Quick Ratio | 0.03 | |||||
Days Inventory | 72.82 | |||||
Days Sales Outstanding | 32.97 | |||||
Days Payable | 672.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -90.12 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 56.8 | |||||
Operating Margin % | -62.57 | |||||
Net Margin % | -71.49 | |||||
EBITDA Margin % | -23.94 | |||||
FCF Margin % | -12.52 | |||||
OCF Margin % | -12.52 | |||||
ROA % | -137.22 | |||||
ROIC % | -9.08 | |||||
3-Year ROIIC % | -19.8 | |||||
ROC (Joel Greenblatt) % | -70.05 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.63 | |||||
EV-to-EBIT | -17.49 | |||||
EV-to-EBITDA | -31.38 | |||||
EV-to-Revenue | 7 | |||||
EV-to-FCF | -55.88 | |||||
Price-to-GF-Value | 0.26 | |||||
Earnings Yield (Greenblatt) % | -5.72 | |||||
FCF Yield % | -23.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:AQSZF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aequus Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.655 | ||
| EPS (TTM) ($) | -0.007 | ||
| Beta | -0.0158 | ||
| 3-Year Sharpe Ratio | 0.02 | ||
| 3-Year Sortino Ratio | 0.03 | ||
| Volatility % | 212.52 | ||
| 14-Day RSI | 62.29 | ||
| 14-Day ATR ($) | 0.000376 | ||
| 20-Day SMA ($) | 0.0014 | ||
| 12-1 Month Momentum % | -48 | ||
| 52-Week Range ($) | 0.0002 - 0.008 | ||
| Shares Outstanding (Mil) | 132.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aequus Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aequus Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Aequus Pharmaceuticals Inc Frequently Asked Questions
What is Aequus Pharmaceuticals Inc(AQSZF)'s stock price today?
The current price of AQSZF is $0.00. The 52 week high of AQSZF is $0.01 and 52 week low is $0.00.
When is next earnings date of Aequus Pharmaceuticals Inc(AQSZF)?
The next earnings date of Aequus Pharmaceuticals Inc(AQSZF) is .
Does Aequus Pharmaceuticals Inc(AQSZF) pay dividends? If so, how much?
Aequus Pharmaceuticals Inc(AQSZF) does not pay dividend.
Guru Commentaries on OTCPK:AQSZF
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Aequus and reVision to Collaborate on Stargardt Disease Program | 2021-08-17 |
Articles on Aequus Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers